Actions from previous meeting

- 1. DHSC to send PHE isolation plan to behavioural scientists (see further action below).
- 2. Others in train.

Situation update

- 3. <u>SAGE</u> is responsible for coordinating science advice across <u>HMG</u>, including from <u>NERVTAG</u>.
- 4. <u>SAGE</u> agreed that <u>SPI-M</u> (Scientific Pandemic Influenza Group on Modelling) is now a formal subgroup of <u>SAGE</u> for the duration of this outbreak.
- 5. A separate group has been convened outside <u>SAGE</u> to consider how <u>UK</u> science can contribute to the international effort to tackle the outbreak.
- 6. <u>DHSC</u> provided an update on current declared cases, deaths and geographic spread.
- 7. 50% of new cases in China are now occurring outside of Wuhan.
- 8. Diagnostics: Specific test should be ready by the end of week, with capacity to run 400 to 500 tests per day. Guidance being rolled out to laboratories in the <u>UK</u>. Sensitivity of test unclear, particularly in early phases of illness or when symptoms are mild. Currently it would not be useful to test asymptomatic individuals, as a negative test result could not be interpreted with certainty.

Current understanding of WN-CoV

- 9. Origin: Current evidence suggests a single point zoonotic outbreak, which is now being sustained by human-to-human transmission. No evidence of ongoing zoonotic transmission.
- 10. Case fatality rate: currently estimated to be lower than SARS, but many uncertainties remain.
- 11. Reproductive number: estimated as between 2 and 3, in accordance with estimates from the Chinese authorities, but these figures are uncertain.
- 12. Doubling rate: estimated at 3 to 4 days.
- 13. Clinical presentations: varied, from mild coughing to fever and pneumonia. Uncertainty regarding clinical symptoms for individuals with mild illness.
- Incubation period: likely to be average of 5 days, but considerable variation in specific cases.
- 15. Duration of infectivity: unknown, but 14 days seems a reasonable estimate.
- 16. There is limited evidence of asymptomatic transmission, but early indications imply some is occurring. PHE developing a paper on this.
- Transmission route: respiratory.
- 18. <u>SAGE</u> urges caution in comparing <u>WN-CoV</u> with <u>SARS</u> and <u>MERS</u>: the transmission dynamics are different.
- 19. Control measures: ideally infection control in healthcare settings and rapid detection of cases.
- 20. It was agreed that Pandemic Influenza infection control guidance should be used as a base case and adapted.